A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

Part of paid clinical trials in San Antonio, Texas.

Sponsor
Novo Nordisk A/S
Study ID
NCT06064006
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • NNC0487-0111 — DRUG
    NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
  • Placebo (NNC0487-0111) — DRUG
    Placebo matching NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.

Study Details

The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as injections under the skin

Key Dates

Start date
Sep 15, 2023
Status verified
Nov 2025
Primary completion
Nov 27, 2024
Completion
Nov 27, 2024

Study Design

Enrollment
125 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NNC0487-0111
    Participants will be randomized to receive NNC0487-0111. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD) Part B, C, D and E: Multiple ascending dose (MAD)
  • Placebo Comparator: Placebo
    Participants will be randomized to receive Placebo. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD). Part B,C,D and E: Multiple ascending dose (MAD).

Primary Outcome Measure

PART A: Number of treatment emergent adverse events (TEAE) [ Time Frame: From pre-dose on Day 1 until completion of the end of study visit, up to Day 25 ]

Locations (2)

FacilityCityStateZIP
ICON Early Phase Services, LLCSan AntonioTexas78209
Novo Nordisk INvestigational SiteSan AntonioTexas78209

Find similar trials in San Antonio, TX

Related Studies